Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of sonelokimab in moderate to severe hidradenitis suppurativa
2021-005928-38Phase 2Completed
- Sponsor
- MoonLake Immunotherapeutics
- Start
- Apr 2022
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sonelokimab in hidradenitis suppurativa (HS) (3 arms), sponsored by MoonLake Immunotherapeutics. Primary endpoint: HiSCR75 at Week 12. Started Apr 2022; status: completed.
02
Drugs
sonelokimab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2021-005928-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005928-38.